Skip Navigation


Rheumatology Advance Access originally published online on January 25, 2007
Rheumatology 2007 46(5):833-841; doi:10.1093/rheumatology/kel451
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
46/5/833    most recent
kel451v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verrecchia, F.
Right arrow Articles by Farge, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verrecchia, F.
Right arrow Articles by Farge, D.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Skin involvement in scleroderma—where histological and clinical scores meet

F. Verrecchia1, J. Laboureau1, O. Verola2, N. Roos1, R. Porcher3, P. Bruneval4, M. Ertault5, K. Tiev6, L. Michel1, A. Mauviel1 and D. Farge1,7

1INSERM U697 Paris, France, 2Service d’anatomopathologie, 3Département de Biostatistique, Hôpital Saint-Louis, 4Service d’anatomopathologie, Hôpital Européen Georges Pompidou, 5Service d’hématologie et de greffe de moelle, Hôpital Saint-Louis, Paris, France, 6Service de Médecine Interne, Hôpital Saint-Antoine, Paris and 7Service de Médecine Interne, Hôpital Saint-Louis, Paris, France.

Correspondence to: F. Verrecchia or D. Farge, INSERM U697 and Service de Médecine Interne, Hôpital Saint-Louis, 1 avenue Claude Vellefaux 75010 Paris, France. E-mail: franck.verrecchia{at}stlouis.inserm.fr or dominique.farge-bancel{at}sls.ap-hop-paris.fr


  Abstract

Objectives. A clinico-pathological study in diffuse systemic sclerosis (SSc) patients was performed to analyse whether the skin histological organization and the pro-fibrotic signals elicited by TGF-ß in fibroblasts vary according to the modified Rodnan skin score (mRSS).

Methods. Twenty-seven SSc patients underwent 45 skin biopsies with simultaneous measure of mRSS before or after treatment by immunosuppressive drugs, with or without autologous peripheral haematopoietic stem cell transplantation (HSCT).

Results. Double-blind optic microscopy analysis of the biopsies standard extracellular matrix stains allowed to define three histological subgroups: 6 with grade 1 weak fibrosis, 30 with grade 2 moderate fibrosis and 9 with grade 3 severe fibrosis. A significant (P < 0.0001) was identified between the grades of fibrosis and the mRSS. In skin fibroblast cultures, Smad3 phosphorylation levels, as well as mRNA steady-state levels of two transforming growth factor (TGF)-ß/Smad3 targets, COL1A2 and PAI-1, increased in parallel with the mRSS. When compared with pre-transplant values the degree of fibrosis observed after HSCT in the papillary and in the reticular dermis decreased in parallel with the fall in mRSS (n = 5 consecutive patients with repeated biopsies).

Conclusions. The histological extent of skin fibrosis correlates closely with the mRSS. Both parameters appeared to regress after HSCT. The extent of TGF-ß signalling activation in SSc skin fibroblasts appears to parallel the severity of disease.

KEY WORDS: Systemic sclerosis, Haematopoietic stem cell transplantation, Fibrosis, TGF-ß, Smad signalling

Submitted 10 November 2006; revised version accepted 15 December 2006.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. Czirjak, I. Foeldvari, and U. Muller-Ladner
Skin involvement in systemic sclerosis
Rheumatology, October 1, 2008; 47(suppl_5): v44 - v45.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Nash, P. A. McSweeney, L. J. Crofford, M. Abidi, C.-S. Chen, J. D. Godwin, T. A. Gooley, L. Holmberg, G. Henstorf, C. F. LeMaistre, et al.
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
Blood, August 15, 2007; 110(4): 1388 - 1396.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.